EUVIMEDEUVIMED entdecken
Crossref

De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care

Hanna L Kleiboeker iD, Margaret R Jorgenson iD, Michael J Scolarici, Jillian L Descourouez iD, Glen E Leverson, Chris Saddler, Didier Mandlebrot iD, David Al-Adra

Clinical Transplantation · 2025

DOI: 10.1111/ctr.70423 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Transplantation, 2025. Verfasst von Hanna L Kleiboeker und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA. Hauptthemen laut MEDLINE: Kidney Transplantation, Cytomegalovirus Infections, Antiviral Agents, Cytomegalovirus. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) is associated with morbidity and mortality after a kidney transplant (KT). Letermovir (LTV) was approved in high‐risk KT recipients, providing an alternative to standard‐of‐care valganciclovir (VGC) associated with reduced myelosuppression.

Methods

Adult patients receiving a kidney transplant with moderate‐risk CMV serostatus between 1/1/2021 and 6/6/2024 were evaluated. Patients were included in VGC or LTV cohort based on de novo prophylaxis regimen. The primary outcomes were efficacy and tolerability.

Results

Four hundred and eight KTRs met inclusion criteria: 316 received VGC, 92 received LTV. Cohorts were comparable; the majority received a primary (84.2% vs. 90.2%, p = 0.566) deceased donor (69.6% vs. 68.5%, p = 0.298) transplant with lymphocyte depleting induction (82.3% vs. 90.2%, p = 0.32). Significantly more patients in the VGC cohort required antiviral dose adjustment (61.7% vs. 1.1%, p < 0.0001). Patients in the LTV cohort were significantly more likely to complete antiviral prophylaxis (63.3% vs. 84.8%, p < 0.0001). Patients in the VGC cohort were significantly more likely to experience leukopenia (65.8% vs. 45.7%, p = 0.0006) and neutropenia (30.7% vs. 12.0%, p = 0.0002) during the first‐year post‐KT. Significantly more patients in the LTV cohort were on the equivalent of >1000 mg mycophenolate/day at 12 months post‐KT (59.9% vs. 74.2%, p = 0.0173). Rates of CMV viremia and clinically significant disease through 1‐year post‐KT were comparable.

Conclusions

De novo LTV in R+ KTRs appears to be safe and effective compared to VGC. This study suggests antiviral prophylaxis is more likely to be successfully completed with LTV and requires less dose titration. Additionally, LTV appears to be associated with less myelosuppression, permitting higher mycophenolate doses at 12 months and avoiding corrective healthcare resource utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney TransplantationCytomegalovirus InfectionsAntiviral AgentsCytomegalovirusMycophenolic AcidGraft RejectionStandard of CareAcetatesQuinazolinesKidney Failure, ChronicPostoperative ComplicationsHumansFemaleMaleMiddle AgedFollow-Up StudiesPrognosisGraft SurvivalRetrospective StudiesRisk FactorsImmunosuppressive AgentsAdultGlomerular Filtration Rate

Substanzen

letermovirAntiviral AgentsMycophenolic AcidImmunosuppressive AgentsAcetatesQuinazolines

Autor:innen und Institutionen

  • Department of Pharmacy, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
  • Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.
  • Department of Surgery, University of Wisconsin-Madison School of Medicine and Public Health, University of Wisconsin Hospital and Clinics, Madison, Wisconsin, USA.

ORCID-Profile: Hanna L Kleiboeker, Margaret R Jorgenson, Jillian L Descourouez, Didier Mandlebrot

Zitieren

APA

Kleiboeker, H. L., Jorgenson, M. R., Scolarici, M. J., Descourouez, J. L., Leverson, G. E., Saddler, C., Mandlebrot, D., & Al-Adra, D. (2025). De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care. Clinical Transplantation. https://doi.org/10.1111/ctr.70423

Vancouver

Kleiboeker HL, Jorgenson MR, Scolarici MJ, Descourouez JL, Leverson GE, Saddler C, et al. De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care. Clinical Transplantation. 2025. doi:10.1111/ctr.70423

BibTeX
@article{Kleiboeker2025,
  author = {Kleiboeker, Hanna L and Jorgenson, Margaret R and Scolarici, Michael J and Descourouez, Jillian L and Leverson, Glen E and Saddler, Chris and Mandlebrot, Didier and Al-Adra, David},
  title = {De Novo Letermovir After Cytomegalovirus Seropositive Kidney Transplant Improves Toxicity and Mycophenolate Tolerance Over the Current Standard of Care},
  journal = {Clinical Transplantation},
  year = {2025},
  doi = {10.1111/ctr.70423}
}
Kostenlos starten →